version 11 1 se (STATA Corporation)
STATA Corporation is a verified supplier 
99
Structured Review
STATA Corporation
version 11 1 se
Version 11 1 Se, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 28063 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/se+version+11%2E1/STATA+11%2E0/pm40624272-39-8-6
Average 99 stars, based on 28063 article reviews
Version 11 1 Se, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 28063 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/se+version+11%2E1/STATA+11%2E0/pm40624272-39-8-6
Average 99 stars, based on 28063 article reviews
version 11 1 se - by Bioz Stars,
2026-10
99/100 stars
Images
Related Articles
Blocking Assay:Article Title: Assessing the association between all-cause mortality and multiple aspects of individual social capital among the older Japanese Article Snippet: Article Title: ST-T wave abnormality in lead aVR and reclassification of cardiovascular risk (from the National Health and Nutrition Examination Survey-III). Article Snippet: 0002-9149/13/$ http://dx.doi.org/1 was to investigate whether ST-T wave amplitude in lead aVR predicts cardiovascular (CV) mortality and if this variable adds value to a traditional risk prediction model. A total of 7,928 participants enrolled in the National Health and Nutrition Examination Survey (NHANES) III with electrocardiographic data available were included.. Each participant had 13.5 – 3.8 years of follow-up.. The study sample was stratified according to ST-segment amplitude and T-wave amplitude in lead aVR. Article Title: Elevation of serum cardiac troponin I in a cross-sectional cohort of asymptomatic subjects with Friedreich ataxia. Article Snippet: a Department of Pediatrics, Division of Neurology, Children's Hospital of Philadelphia, PA, United States b Department of Neurology, University of Pennsylvania, Philadelphia, PA, United States c Department of Cardiology, Cooper University Hospital, Camden, NJ, United States d Department of Pediatrics, Division of Cardiology, Children's Hospital of Philadelphia, PA, United States e Penwest Pharmaceuticals, Patterson, NY, United States f Department of Cardiology, University of Pennsylvania, Philadelphia, PA, United States g Department of Pediatrics, Division of Endocrinology, Children's Hospital of Philadelphia, PA, United States Article Title: Excess Infant Mortality Among Native Hawaiians: Identifying Determinants for Preventive Action Article Snippet: We conducted descriptive analyses in SAS version 9.2 (SAS Institute, Cary, NC) and the Article Title: Cross-Sectional Analysis of Electrocardiograms in a Large Heterogeneous Cohort of Friedreich Ataxia Subjects Article Snippet: Electrocardiogram Criteria in Pediatric Subjects table ft1 table-wrap mode="anchored" t5 Table 2 caption a7 Electrocardiogram Feature Criteria Right atrial enlargement P wave >2.5 mV in leads II, III, or aVF Left atrial enlargement P wave> 0.12 sec in leads II, III, or aVF, or P wave> 0.04 sec and −1mV (negative deflection) in V 1 Right ventricular hypertrophy R wave >6mV or rsR′ >0mV in V 1 , or S wave >7 mV in V 5 or V 6 , or R wave in V1 + S wave in V 6 >10mV Left ventricular hypertrophy R wave > 11mV in aVL, or R wave > 25mV in V 5 or V 6 , or R wave in V 6 + S wave in V 1 >35mV, or S wave in V 3 + R wave in aVL >24 mV in men and >20 mV in Article Title: Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic Pancreatic Cancer. Article Snippet: Objectives: This study is a meta-analysis of prior publications evaluating the impact of modified FOLFIRINOX (mFIO) regimens in advanced pancreatic cancer.. Methods: We performed a meta-analysis of studies published in PubMed, Scopus and Web of Science (1950-2016) on December 2016.. Inclusion criteria were: randomized trials, prospective or retrospective cohorts; patients with metastatic pancreatic adenocarcinoma; use of mFIO or FOLFIRINOX (FIO) chemotherapy and available information of at least 1 efficacy endpoint (response rate, progression free survival or overall survival). Article Title: Characterization of clinical serum cardiac biomarker levels in individuals with Friedreich ataxia. Article Snippet: Friedreich ataxia is a progressive autosomal recessive neurodegenerative disorder characterized by ataxia, dyscoordination, and cardiomyopathy.. A subset of patients with Friedreich ataxia have elevated levels of serum cardiac troponin I, but associations with disease outcomes and features of cardiomyopathy remain unclear.. In this study, we characterized clinically obtained serum cardiac biomarker levels including troponin I, troponin T, and B-type natriuretic peptide in subjects with Friedreich ataxia and evaluated their association with markers of disease. Functional Assay:Article Title: Assessing the association between all-cause mortality and multiple aspects of individual social capital among the older Japanese Article Snippet: Article Title: ST-T wave abnormality in lead aVR and reclassification of cardiovascular risk (from the National Health and Nutrition Examination Survey-III). Article Snippet: 0002-9149/13/$ http://dx.doi.org/1 was to investigate whether ST-T wave amplitude in lead aVR predicts cardiovascular (CV) mortality and if this variable adds value to a traditional risk prediction model. A total of 7,928 participants enrolled in the National Health and Nutrition Examination Survey (NHANES) III with electrocardiographic data available were included.. Each participant had 13.5 – 3.8 years of follow-up.. The study sample was stratified according to ST-segment amplitude and T-wave amplitude in lead aVR. Article Title: Elevation of serum cardiac troponin I in a cross-sectional cohort of asymptomatic subjects with Friedreich ataxia. Article Snippet: a Department of Pediatrics, Division of Neurology, Children's Hospital of Philadelphia, PA, United States b Department of Neurology, University of Pennsylvania, Philadelphia, PA, United States c Department of Cardiology, Cooper University Hospital, Camden, NJ, United States d Department of Pediatrics, Division of Cardiology, Children's Hospital of Philadelphia, PA, United States e Penwest Pharmaceuticals, Patterson, NY, United States f Department of Cardiology, University of Pennsylvania, Philadelphia, PA, United States g Department of Pediatrics, Division of Endocrinology, Children's Hospital of Philadelphia, PA, United States Article Title: Excess Infant Mortality Among Native Hawaiians: Identifying Determinants for Preventive Action Article Snippet: We conducted descriptive analyses in SAS version 9.2 (SAS Institute, Cary, NC) and the Article Title: Cross-Sectional Analysis of Electrocardiograms in a Large Heterogeneous Cohort of Friedreich Ataxia Subjects Article Snippet: Electrocardiogram Criteria in Pediatric Subjects table ft1 table-wrap mode="anchored" t5 Table 2 caption a7 Electrocardiogram Feature Criteria Right atrial enlargement P wave >2.5 mV in leads II, III, or aVF Left atrial enlargement P wave> 0.12 sec in leads II, III, or aVF, or P wave> 0.04 sec and −1mV (negative deflection) in V 1 Right ventricular hypertrophy R wave >6mV or rsR′ >0mV in V 1 , or S wave >7 mV in V 5 or V 6 , or R wave in V1 + S wave in V 6 >10mV Left ventricular hypertrophy R wave > 11mV in aVL, or R wave > 25mV in V 5 or V 6 , or R wave in V 6 + S wave in V 1 >35mV, or S wave in V 3 + R wave in aVL >24 mV in men and >20 mV in Article Title: Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic Pancreatic Cancer. Article Snippet: Objectives: This study is a meta-analysis of prior publications evaluating the impact of modified FOLFIRINOX (mFIO) regimens in advanced pancreatic cancer.. Methods: We performed a meta-analysis of studies published in PubMed, Scopus and Web of Science (1950-2016) on December 2016.. Inclusion criteria were: randomized trials, prospective or retrospective cohorts; patients with metastatic pancreatic adenocarcinoma; use of mFIO or FOLFIRINOX (FIO) chemotherapy and available information of at least 1 efficacy endpoint (response rate, progression free survival or overall survival). Article Title: Characterization of clinical serum cardiac biomarker levels in individuals with Friedreich ataxia. Article Snippet: Friedreich ataxia is a progressive autosomal recessive neurodegenerative disorder characterized by ataxia, dyscoordination, and cardiomyopathy.. A subset of patients with Friedreich ataxia have elevated levels of serum cardiac troponin I, but associations with disease outcomes and features of cardiomyopathy remain unclear.. In this study, we characterized clinically obtained serum cardiac biomarker levels including troponin I, troponin T, and B-type natriuretic peptide in subjects with Friedreich ataxia and evaluated their association with markers of disease. |